Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

EGFR testing and erlotinib use in non-small cell lung cancer patients in Kentucky.

PloS one - 1 Jan 2020

Larson Kara L, Huang Bin, Chen Quan, Tucker Thomas, Schuh Marissa, Arnold Susanne M, Kolesar Jill M

Abstract excerpt

This study determined the frequency and factors associated with EGFR testing rates and erlotinib treatment as well as associated survival outcomes in patients with non small cell lung cancer in Kentucky. Data from the Kentucky Cancer Registry (KCR) linked with health claims from Medicaid, Medicare and private insurance groups were evaluated. EGFR testing and erlotinib prescribing were identified using ICD-9...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Erlotinib Hydrochloride
Share to Healthcare Disparities

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Poverty

Share to Precision Medicine

Share to Registries

Share to Sex Factors

Share to Survival Analysis

Share to United States

Source

Open in PubMed Open full text

Identifiers

PMID: 32810185
DOI: 10.1371/journal.pone.0237790
PMCID: PMC7433873

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

EGFR testing and erlotinib use in non-small cell lung cancer patients in Kentucky.PMID 32810185Read ↗

Utilisation and Determinants of Epidermal Growth Factor Receptor Mutation Testing in Patients with Non-small Cell Lung Cancer in Routine Clinical Practice: A Global Systematic Review.Semantic proximity Read ↗

Utilization Patterns and Trends in Epidermal Growth Factor Receptor (EGFR) Mutation Testing Among Patients With Newly Diagnosed Metastatic Lung Cancer.Semantic proximity Read ↗

EGFR mutation testing and TKI treatment patterns among veterans with stage III and IV non-small cell lung cancer.Semantic proximity Read ↗

Underutilization and disparities in access to EGFR testing among Medicare patients with lung cancer from 2010 - 2013.Semantic proximity Read ↗

EGFR-mutation testing and TKI treatment patterns in locally advanced and metastatic NSCLC in Norway - A nationwide retrospective cohort study.Semantic proximity Read ↗

Usage of epidermal growth factor mutation testing and impact on treatment patterns in non-small cell lung cancer: An international observational study.Semantic proximity Read ↗

Molecular Biomarker and Programmed Death-Ligand 1 Expression Testing in Patients With Advanced Stage Non-small Cell Lung Cancer Across North Carolina Community Hospitals.Semantic proximity Read ↗

Epidermal Growth Factor Receptor Mutational Testing and Erlotinib Treatment Among Veterans Diagnosed With Lung Cancer in the United States Department of Veterans Affairs.Semantic proximity Read ↗

Study of patient characteristics, treatment patterns, EGFR testing patterns and outcomes in real-world patients with EGFRm+ non-small cell lung cancer.Semantic proximity Read ↗

Utilization and costs of epidermal growth factor receptor mutation testing and targeted therapy in Medicare patients with metastatic lung adenocarcinoma.Semantic proximity Read ↗

The impact of erlotinib use in non-small-cell lung cancer patients treated in a private reference general hospital and in a private cancer clinic from 2005 to 2011.Semantic proximity Read ↗

Utilization of epidermal growth factor receptor (EGFR) testing in the United States: a case study of T3 translational research.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.